Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3

Conclusion: We achieved satisfactory anti-tumor activity using trastuzumab plus LMAb1 in trastuzumab-resistant ovarian cancer model. In similar cases, not only acquired but also de novo, good curative effect might be achieved using combined antibody therapy strategies.

http://www.ovarianresearch.com/content/7/1/103

Source: Journal of Ovarian Research - November 26, 2014 Category: Cancer & Oncology Authors: Wei WangYan ZhangMing LvJiannan FengHui PengJing GengZhou LinTingting ZhouXinying LiBeifen ShenYuanfang MaChunxia Qiao Source Type: research